The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...
Surbhi Sidana, MD, discusses the versatility of iberdomide and the approved Iber-Dd regimen in relapsed multiple myeloma. Surbhi Sidana, MD, associate professor of medicine at Stanford University and ...
A prospective Canadian study suggests that moving beyond narrow, cancer-specific molecular panels toward broader genomic ...
In an interview with Targeted Oncology™, Marcus Neubauer, MD, of The US Oncology Network, discusses the signs of physician ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results